Summary
The Danish drugmaker also revealed an improved outlook for the year.
Novo Nordisk stock is sliding again — and the Wegovy pill’s surprise miss is partly to blame
Source & full coverage: this summary is aggregated from MarketWatch, the original publisher. Read the complete report for full context, data and quotes.
Read the original report at MarketWatch →
